# Amgen Adopts GPT-5 for Biotechnology Applications

OpenAI announced via Twitter that pharmaceutical giant Amgen is now using GPT-5, marking one of the first public case studies of the latest AI model in the biotechnology sector.

While OpenAI's tweet was brief, the partnership represents a significant milestone for both companies. Amgen, one of the world's largest independent biotechnology firms, is known for developing treatments for serious illnesses including cancer, kidney disease, and rheumatoid arthritis.

**What Changed**

This marks Amgen's adoption of GPT-5, OpenAI's newest and most advanced language model. The move signals growing confidence in AI tools among pharmaceutical companies for drug discovery, research analysis, and potentially clinical applications.

**Why It Matters**

The pharmaceutical industry has been cautiously exploring AI integration, and a major player like Amgen publicly embracing GPT